Research
Tirzepatide dose-response: 5, 10, and 15 mg
Tirzepatide shows a clear dose-response across its three labeled strengths (5, 10, 15 mg weekly): SURMOUNT-1 reported greater weight loss at higher do
Tirzepatide shows a clear dose-response across its three labeled strengths (5, 10, 15 mg weekly): SURMOUNT-1 reported greater weight loss at higher doses, up to ~20.9%. As with semaglutide, this dose-response is established within the studied range, not below it.
What the trials establish
SURMOUNT-1 tested 5, 10, and 15 mg and found increasing mean weight loss with dose, peaking near 20.9% at 15 mg — the clearest dose-response picture among these drugs because three doses were studied head-to-head against placebo. SURMOUNT-2 confirmed substantial loss in people with type 2 diabetes.
The dual GIP/GLP-1 mechanism is the leading explanation for the larger effect versus single-agonist semaglutide. But the studied floor is 5 mg; a compounded 'microdose' sits below even that, in territory no trial mapped.
So while tirzepatide's dose-response is the best-characterized of the two within its labeled range, that characterization stops at the lowest studied dose and says nothing reliable about a microdose.
| Trial | Population | N | Result | Citation | Identifiers |
|---|---|---|---|---|---|
| SURMOUNT-1 | Adults with obesity, without diabetes | 2,539 | Up to about -20.9% at 15 mg vs -3.1% placebo | Jastreboff AM, et al. N Engl J Med 2022;387(3):205-216 | NCT04184622 · PMID 35658024 · DOI |
| SURMOUNT-2 | Adults with obesity and type 2 diabetes | 938 | About -12.8% to -14.7% vs -3.2% placebo | Garvey WT, et al. Lancet 2023;402(10402):613-626 | NCT04657003 · PMID 37385274 · DOI |
Identifiers verified against ClinicalTrials.gov and PubMed. Machine-readable dataset: studies.json · studies.csv.
What remains unknown
Across this topic, the recurring gap is the same: the randomized evidence describes approved products at studied doses, while compounded and deliberately sub-therapeutic 'microdose' use sits outside it. This page marks that boundary rather than blurring it.
What the evidence shows
- The cited trials carry verified NCT, PMID, and DOI identifiers and studied approved products at labeled doses.
- Findings here reflect those trials' actual results and populations.
What the evidence does not show
- That a compounded or microdose version reproduces these results — it has not been studied.
- That approved-product evidence transfers automatically to compounded formulations.
Frequently asked questions
Is tirzepatide dose-dependent?
Yes — SURMOUNT-1 showed more weight loss at higher of its 5/10/15 mg doses.
Is a tirzepatide microdose studied?
No — the lowest studied dose is 5 mg; below that is uncharacterized.
Related: evidence database · research hub. Compounded medications are not FDA approved.
Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.